Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition) ›› 2025, Vol. 19 ›› Issue (02): 116-123. doi: 10.3877/cma.j.issn.1674-1358.2025.02.007

• Research Articles • Previous Articles     Next Articles

Value of procalcitonin level in identification of bacterial bronchitis pathogen types and value of guidance of moxifloxacin application

Fan Yang1,()   

  1. 1. epartment of Clinical Laboratory, Beijing Gulou Hospital of Traditional Chinese Medicine, Beijing 100009, China
  • Received:2024-12-16 Online:2025-04-15 Published:2025-06-10
  • Contact: Fan Yang

Abstract:

Objective

To explore the value of procalcitonin (PCT) level in identification of bacterial bronchitis pathogen types, and investigate the value of guidance of moxifloxacin application.

Methods

Total of 236 patients with bacterial bronchitis admitted to Beijing Gulou Hospital of Traditional Chinese Medicine from November 2018 to December 2023 were selected. Bacterial pathogens types of the patients were detected by fully automatic bacterial identification instrument, and PCT levels of patients in Grampositive group (160 cases) and Gram-negative group (76 cases) were compared. The diagnostic value of PCT level for bacterial bronchial pathogen types identification were analyzed by receiver operating characteristic curve (ROC). The research subjects were randomly divided into PCT guidance group (Moxifloxacin was given to patients based on PCT level) and control group (Moxifloxacin was given as routine treatment) by a numerical table method, with 118 cases in each group. The disappearance time of symptoms, levels of inflammatory factors and the clinical efficacy of both groups of patients were compared, respectively.

Results

Among the 236 patients with bacterial bronchitis, 160 strains of Gram-positive bacteria were detected, with a detection rate of 67.80%; 76 strains of Gram-negative bacteria were detected, with a detection rate of 32.20%.Compared with the Gram-positive bacterial group [2.27 (0.72, 6.22) ng/ml], the PCT level of patients in Gramnegative bacterial group [7.13 (2.50, 17.65) ng/ml]was significantly increased, with significant difference(U = 6.365, P < 0.001). The ROC curve analysis of PCT level for pathogen type identification in patients with bacterial bronchitis showed that the Yoden index (0.535) was the highest at a PCT level of 5.42 ng/ml, with corresponding sensitivity and specificity of 0.739 and 0.796, respectively. The area under ROC curve (AUC)was 0.784. The disappearance time of wheezing [(2.77 ± 0.83) d], temperature recovery time [(2.68 ± 0.81) d], cough disappearance time [(3.52 ± 1.41) d]and duration of hospitalization [(5.67 ± 2.46) d]of patients in PCT guidance group were significantly lower than those of the control group [(4.36 ± 1.32) d, (4.53 ± 1.44) d, (6.27 ± 1.39) d and (9.12 ± 3.52) d],with significant differences (t = 11.077, 12.163, 15.088, 8.727, all P < 0.001). After 1 day, 7 days and 14 days of treatment, the cough symptom scores and C-reactive protein (CRP) levels of patients in PCT guidance group were significantly lower than those of the control group; After 7 days and 14 days of treatment, the levels of PCT and white blood cell count (WBC) of patients in PCT guidance group were significantly lower than those of the control group, with significant differences (all P < 0.001). The total effective rate of patients in PCT guidance group after 14 days of treatment was 93.22% (110/118), significantly higher than that of control group (77.12%,91/118), with significant differences (χ2 = 12.110, P = 0.001).

Conclusions

Serum PCT level can be used as an effective indicator for the pathogenic type identification of bacterial bronchitis. By monitoring serum PCT level,the use of moxifloxacin of patients with bacterial bronchitis can be guided.

Key words: Procalcitonin, Bacterial bronchitis, Type of pathogenic bacteria, Moxifloxacin

京ICP 备07035254号-20
Copyright © Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), All Rights Reserved.
Tel: 010-85322058 E-mail: editordt@163.com
Powered by Beijing Magtech Co. Ltd